Eyenovia’s (EYEN) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a research note released on Friday morning,Benzinga reports. The firm currently has a $2.00 price target on the stock.

Eyenovia Stock Down 4.2 %

EYEN stock opened at $1.38 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The company has a 50-day moving average of $2.66 and a two-hundred day moving average of $17.64. Eyenovia has a 52-week low of $1.28 and a 52-week high of $124.80. The stock has a market capitalization of $1.92 million, a price-to-earnings ratio of -0.02 and a beta of 1.29.

Institutional Investors Weigh In On Eyenovia

A hedge fund recently raised its stake in Eyenovia stock. Geode Capital Management LLC lifted its stake in Eyenovia, Inc. (NASDAQ:EYEN) by 3.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 577,393 shares of the company’s stock after buying an additional 19,399 shares during the period. Geode Capital Management LLC owned about 41.54% of Eyenovia worth $84,000 at the end of the most recent reporting period. Institutional investors own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.